Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth Parliament, was introduced to ensure that therapeutic goods available in Australia are of acceptable quality, safety, and efficacy. This Act fills the gap by regulating the manufacture, supply, and advertising of therapeutic goods, aiming to protect public health. The Act's policy objective is to ensure that therapeutic goods meet required standards, thereby safeguarding the health and safety of consumers. The recent publication by the Therapeutic Goods Administration, through Dr. Katherine Clark as the delegate of the Secretary, highlights the ongoing commitment to maintaining these standards by granting licences to specific manufacturers, such as Astral Scientific Pty Ltd, Logikal Health Products Pty Ltd, and Euro Fins Chemical Analysis Pty Ltd. This process ensures that these companies meet the stringent regulatory requirements necessary to produce therapeutic goods in Australia.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods within Australia, establishing a framework for the approval, manufacture, supply, and advertising of such products. This Act applies to individuals and entities involved in the manufacture, supply, or advertising of therapeutic goods, which include medicines, medical devices, blood and blood components, tissues, and in vitro diagnostic goods. The Act’s scope encompasses the entire Commonwealth of Australia, ensuring a cohesive regulatory approach across states and territories. Notably, the Act excludes certain products such as tobacco products, which are regulated under different legislation. The application of the Therapeutic Goods Act 1989 can be further refined through subordinate instruments, which may specify detailed requirements or conditions for particular types of therapeutic goods. The publication of the list of manufacturers granted a licence to manufacture therapeutic goods, as seen in the notice by the Therapeutic Goods Administration, is an example of how the Act’s provisions are implemented to ensure compliance and maintain the quality and safety of therapeutic goods available in the Australian market.

Key Provisions

The Therapeutic Goods Act 1989, as referenced in section 38, facilitates the regulation of therapeutic goods within Australia. Under this provision, the Secretary of the Department of Health, Therapeutic Goods Administration, has the authority to grant licences for the manufacture of therapeutic goods to eligible parties. This legislative framework ensures that only entities meeting stringent quality and safety standards are permitted to manufacture therapeutic goods, thus protecting public health. Section 38 explicitly mentions that Astral Scientific Pty Ltd, Logikal Health Products Pty Ltd, and Euro Fins Chemical Analysis Pty Ltd have been granted licences to manufacture therapeutic goods, each identified by a unique licence number. Entities granted licences under section 38 of the Therapeutic Goods Act 1989 are required to comply with specific obligations. These include maintaining rigorous quality control measures, adhering to Good Manufacturing Practices (GMP), and ensuring that all therapeutic goods produced meet the standards set out in the Therapeutic Goods Regulations 1990. Additionally, licence holders must submit regular reports to the Therapeutic Goods Administration, detailing their compliance with the stipulated requirements. Failure to meet these obligations can result in the suspension or revocation of the manufacturing licence. Breaches of the Therapeutic Goods Act 1989 can result in both civil and criminal penalties. For instance, knowingly manufacturing or supplying therapeutic goods that do not comply with the legislative requirements can lead to significant fines and imprisonment. The maximum penalty for individuals who commit such offences includes fines of up to $330,000 and imprisonment for up to five years. For corporations, the fines can be substantially higher, reaching up to $1.65 million. Furthermore, the Act provides for the possibility of court-ordered injunctions to prevent further non-compliance, thereby reinforcing the seriousness with which such violations are treated.